By Peter J. O’Dwyer, MD (left)
and Mitchell D. Schnall, MD, PhD

As we look forward to our semi-annual meeting in Fort Lauderdale, we recognize and have empathy for the suffering many in Florida are still experiencing following the recent catastrophic hurricanes and their aftermath. Meeting registration numbers are already high, and we look forward to a highly interactive and effective meeting. As we finalize preparations toward a renewal of the NCTN grant in February, we find it remarkable how the cancer research landscape has evolved in the past five years.

The successful completion of two landmark trials in genomics and screening (NCI-MATCH and TMIST) will empower and invigorate the next generation of studies in these areas. Successful approaches to accomplishing clinical trials in new ways, as implemented by CTEP during the pandemic, have had lasting effects on trial design elements (decentralization, remote trial functions, drug distribution). There is enthusiasm to consider these strategies for inclusion as we plan new studies. A renewed focus on speed and simplicity in answering urgent therapeutic questions, as emphasized by FDA and Friends of Cancer Research, has opened a whole field of “pragmatic trials” and a dialogue regarding their optimal use. The success of a SWOG-led lung cancer trial with focused and limited study requirements will be replicated in EA and other groups going forward.

Additionally, the recognition of the importance of population-wide assessment of the outcomes of therapy (as exemplified by Real-World Data and Real-World Evidence) has led EA to work with the FDA to implement such trials. Simply put, a learning environment that may comprise 3-7% of cancer patients (as represented in existing trials) can be expanded to 30% or more. This can be achieved using analytical approaches that bring the outcomes of patients treated outside of trials into our collective knowledge base to accelerate progress. To accelerate cures. To better realize the potential and the meaning of Precision Medicine as practically implemented for patients.

Along with these changes, we partner with NCI in realizing timely and complete analysis of correlative endpoints of trials through public-private partnerships that have already been embarked upon. The Cooperative Groups together have provided a framework for discussion and implementation to address both the funding and the process changes that can remove barriers to data generation. The research structures going forward will further center the patient voice in setting priorities, demanding speed and efficiency, and in reaching out to potential partners to help us with these goals.

We expect the next five years to be equally an opportunity for creative change. The successes of the Health Equity Committee, together with our partners at the National Medical Association, as well as the Task Force on Advancement for Women in engaging a more diverse membership base will bring new ideas and perspectives. Each semi-annual meeting is a brick in the wall, raising opportunities and sealing deals. See you in Florida.

Read the October 2024 issue here.